HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Infectious Disease2 papers

Extensively drug resistant tuberculosis

Last edited: 4/10/2026

Overview

Extensively drug-resistant tuberculosis (XDR-TB) is a significant global public health concern, characterized by resistance to multiple anti-tuberculosis drugs. The emergence of newer forms of active tuberculosis necessitates the development of novel therapeutics.

Diagnosis

No information provided in the abstracts.

Management

No information provided in the abstracts.

Special Populations

No information provided in the abstracts.

Key Recommendations

  • Further research is needed to identify novel therapeutics targeting human host factors for active tuberculosis disease 1.
  • Statistical meta-analysis of human gene transcriptomes can identify differentially expressed genes in active tuberculosis disease 1.
  • Gene ontology analysis can reveal that these differentially expressed genes are major contributors to immune responses 1.
  • Pathway enrichment analyses can identify human canonical pathways related to other infectious diseases 1.
  • Comparison of differentially expressed genes with tuberculosis genome-wide association study datasets can reveal the presence of genetic variants in their proximity 1.

    • References

    1 Ponnusamy N, Arumugam M. Meta-analysis of active tuberculosis gene expression ascertains host directed drug targets. Frontiers in cellular and infection microbiology 2022. link

    Original source

    1. [1]
      Meta-analysis of active tuberculosis gene expression ascertains host directed drug targets. — Ponnusamy N, Arumugam M Frontiers in cellular and infection microbiology (2022)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG